X4 Pharmaceuticals (XFOR) Misses Q4 EPS by 56c

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q4 EPS of ($1.24), $0.56 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• After-Hours Stock Movers: FDX, CBRS, NKE
• SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters